Aim Bulletin
Capital Metals reports progress at Eastern Minerals Project
Capital Metals, a mineral sands company on the verge of mine development at the high-grade Eastern Minerals Project in Sri Lanka, reported substantial progress in securing necessary permits and approvals for its operations on Thursday.
4basebio client gets approval to start trial in Australia
Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.
Cambridge Cognition forms scientific advisory board
Digital brain health solutions developer Cambridge Cognition announced the creation of a scientific advisory board on Thursday.
Mercia Asset Management secures two new BBB mandates
Mercia Asset Management announced an expanded role in bolstering regional business growth on Thursday, with the acquisition of two new fund mandates from the British Business Bank (BBB).
XLMedia to sell Europe, Canada assets for up to $42.5m
AIM-listed XLMedia said on Thursday that it has agreed to sell its Europe and Canada assets for up to $42. 5m to performance marketing and sports betting media firm Gambling. com (GAMB).
Feedback secures funding for Oldham pilot
Feedback has secured £50,000 in funding to initiate a Community Diagnostic Centre (CDC) pathway pilot with the Oldham CDC, it announced on Thursday, managed by the Northern Care Alliance.
Victoria promotes Roberto Moreno to group strategy chief
Flooring specialist Victoria announced the appointment of Roberto Moreno as its new group chief strategy officer and principal duty manager on Thursday.
Avacta reaches milestone in AVA6000 dose escalation
Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead ‘preCISION’ drug, on Thursday.
PetroTal ends year in line with guidance
PetroTal said in an update on Thursday that in the fourth quarter, it saw average sales and production of 15,033 and 14,865 barrels of oil per day, respectively.
Judges Scientific revenue rises, outlook more uncertain
Scientific instrument sector investor Judges Scientific reported a 20% uptick in 2023 revenue in its final results on Thursday, reaching £136. 1m, although its shares were sliding on a more uncertain outlook for 2024.